ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0294

Tired T-Cells and Monocytes with Malaise: Investigating the Links Between Cellular Iron Deficiency and Mitochondrial Dysfunction in Systemic Lupus Erythematosus
Abstract Number: 0295

CCL3L3–null Status May Predispose to Systemic Lupus Erythematosus and Non-scarring Alopecia
Abstract Number: 0296

Investigating the Differences in ANA Specificities Between Asymptomatic and Symptomatic ANA+ Individuals
Abstract Number: 0297

Towards a Glucocorticoid Exposure Signature in SLE: Effects of Type I Interferon
Abstract Number: 0298

Local Genetic Ancestry Associations with Clinical Features of Systemic Lupus Erythematosus
Abstract Number: 0299

The Minor Protective Allele at rs1876453 Is Associated with Increased Age of Onset of Systemic Lupus Erythematosus
Abstract Number: 0300

Exposure to Topical Antimicrobials Reduces Inflammatory Gene Expression in Cutaneous Lupus Lesional Skin
Abstract Number: 0301

Genetic Associations and Polygenic Risk Assessment in Incomplete Lupus Erythematosus
Abstract Number: 0302

Longitudinal Study of Acute SLE Flare Reveals Dynamic Changes in Multiple Immune Cell Subsets
Abstract Number: 0303

SLE Patients Stratify into Distinct Clusters Based on Their Peripheral Blood Immunologic Phenotype During Acute Flare
Abstract Number: 0304

Type I Interferon Inhibits Glucocorticoid-Induced Leucine Zipper (GILZ) Expression and Upregulation by Glucocorticoids
Abstract Number: 0305

A Delphi Consensus Study to Standardize Terminology for the Pre-clinical Phase of Psoriatic Arthritis
Abstract Number: 0306

Characteristics of Patients with Early Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Abstract Number: 0307

Longitudinal Analysis of the Patient Pathways to Diagnosis of Psoriatic Arthritis
Abstract Number: 0308

Delay in Transition from Psoriasis to Psoriatic Arthritis: A Population Based Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].